Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Barclays Global Healthcare Conference 2021
10 slides from Bausch Health Companies's conference presentation, Mar 9, 2021
Slide 1: Barclays Global Healthcare Conference
Barclays Global Healthcare Conference March 9, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, “forward-looking statements”), including, but not limited to, expected initiation of studies or trials or expec
Slide 3: Key Salix Pipeline Overview
Key Salix Pipeline Overview 1 Investigational Proposed Indications Pre-Clinical Phase I Phase 2 Phase 3 Formulation RED-C Program - Reduction of Rifaximin SSD Early Decompensation in Cirrhosis (Solid Soluble Hepatology Dispersion) in a Prevention of the first Rifaximin SSD IR tablet occurrence of he
Slide 4: Amiselimod Capsules
Amiselimod Capsules1 Mild to Moderate Ulcerative Colitis • Amiselimod is a new oral selective S1P2 receptor modulator • Amiselimod shows potent selectivity for S1P1 receptor and no distinct agonist activity for S1P2 or S1P3 receptors • Thorough QT/QTc trial demonstrated clean cardiac profile; data p
Slide 5: Novel Rifaximin Formulations
4 Novel Rifaximin Formulations Unique and novel rifaximin formulations are in development to address unmet medical needs Rifaximin solid soluble dispersion (SSD) in a tablet Combination of rifaximin with a mucolytic agent Rifaximin liquid gel capsules Rifaximin timed release coated beads in capsules
Slide 6: Rifaximin Solid Soluble Dispersion (SSD) in a Tablet
Rifaximin Solid Soluble Dispersion (SSD) in a Tablet RED-C Program • RED-C Program - Reduction of Early Decompensation in Cirrhosis • “Upstream” approach intended to prevent the first occurrence of hepatic encephalopathy (HE) in mild cirrhosis • Will also investigate: Spontaneous bacterial peritonit
Slide 7: Combination of Rifaximin with a Mucolytic Agent
Combination of Rifaximin with a Mucolytic Agent Irritable Bowel Syndrome - Diarrhea Cedars-Sinai Collaboration • Collaboration with Cedars-Sinai • Combination of rifaximin with a mucolytic agent (N-acetyl cysteine) • Liberation of resident noxious bacteria in mucous layer will result in better kill
Slide 8: Rifaximin Liquid Gel Capsules
Rifaximin Liquid Gel Capsules Small Intestinal Bacterial Overgrowth (SIBO) • Targeted for small intestine bacterial overgrowth (SIBO) • Currently there is no approved medication indicated for SIBO • Designed to release in the small bowel Timeline • Working with FDA on the development of proprietary
Slide 9: Rifaximin Timed Release Coated Beads in Capsules
Rifaximin Timed Release Coated Beads in Capsules Sickle Cell Anemia • Orphan disease designation granted October 2020 • Dysbiosis (disordered gut microbiome) in sickle cell patients is associated with more frequent episodes where “sickled” red blood cells and circulating activated neutrophils (CANs)
Slide 10: Rifaximin development timeline 2019-2027
2019 2020 2021 2022 2023 2024 2025 2026 2027 Rifaximin solid soluble dispersion (SSD) in a tablet1 Phase 3 NDA Approval RED-C Trial Start Expected Expected Combination of rifaximin with a mucolytic agent1 Irritable Bowel Syndrome - Diarrhea Phase 2 Phase 3 NDA Approval Cedars-Sinai Trial Start Trial
Bausch Health Companies — Barclays Global Healthcare Conference 2021 on 6ix